Since ezetimibe is the first agent of a novel class of selective cholesterol absorption inhibitors, and in light of its benefits -- limited drug interactions, excellent safety profile, ease of dosing, and minimal laboratory monitoring, allowing more patients to reach their LDL goal -- its addition to formularies should be considered. Ezetimibe is supplied as 10-mg, white, capsule-shaped tablets; the average wholesale price is $72.38 for 30 tablets. The combination of ezetimibe with a statin at a reduced dose may allow for a drug regimen comparable in price to that of a maximal dose of a statin alone ( Table 3 ). Cost-effectiveness also will depend on institution-specific contract pricing; therefore, additional pharmacoeconomic analyses of this combination are warranted.
Pharmacotherapy. 2003;23(11) © 2003 Pharmacotherapy Publications
Copyright © 1999, Pharmacotherapy Publications, Inc., All rights reserved.
Cite this: Ezetimibe: A Selective Cholesterol Absorption Inhibitor - Medscape - Nov 01, 2003.